ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it will be exhibiting at…Read More
Related Posts
New algorithm can predict diabetic kidney disease
LA JOLLA, CALIF. - May 15, 2023 - Researchers from Sanford Burnham Prebys and the Chinese University of Hong Kong have developed a computational approach to predict whether a person…
DERMTECH SURPASSES 200000 CUMULATIVE BILLABLE SAMPLES FOR THE DERMTECH MELANOMA TEST MarketScreener
SAN DIEGO - DermTech, Inc. (NASDAQ: DMTK) ('DermTech' or the 'Company'), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the DermTech Melanoma Test…
Study discovers new therapy for rapid eye movement sleep behaviour disorder
New York [US], May 29 (ANI): Mount Sinai researchers claim to have discovered a novel therapy for rapid eye movement (REM) sleep behaviour disorder. This disorder affects approximately 3 million…
